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Graphical Abstract 
 
 
Abstract 
Image guided drug delivery has gained significant attention during the last few years. Labelling 
nanoparticles or macromolecules and monitoring their fate in the body provides information 
that can be used to modulate their biodistribution and improve their pharmacokinetics. In 
this study we label antibodies and monitor their distribution in the tumours post intravenous 
injection. Using Focused Ultrasound (FUS, a non-invasive method of hyperthermia) we 
increase the tumour temperature to 42°C for a short period of time (3-5 min) and we observe 
an increased accumulation of labelled antibody. Repetition of focused ultrasound induced 
hyperthermic treatment increased still further the accumulation of the antibodies in the 
tumour. This treatment also augmented the accumulation of other macromolecules non-
specific in the tumour, such as IgG and albumin. These effects may be used to enhance the 
therapeutic efficiency of antibodies and/or targeted nanoparticles.  
Abbreviations: DPBS, Dulbecco's Phosphate-Buffered Saline; DMSO, dimethyl sulfoxide;  
EGFR, Epidermal Growth Factor receptor; FDA, U S Food and Drug Administration; FUS, 
Focused 
Ultrasound  
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Focused Ultrasound; HER-2, human epidermal Growth Factor Receptor 2; HIFU, High Intensity 
Ultrasound; IgG, Immunoglobulin G antibody; MRI, Magnetic Resonance Imaging; NIRF, Near 
Infrared Fluorescence, PET, Positron Emission Tomography; SDS-PAGE, sodium dodecyl 
sulfate polyacrylamide gel electrophoresis; SHO, SCID Hairless Outbred; TIPS, Therapy and Imaging 
Probe System; XL750, XenoLight CF750 dye;  
 
Keywords: focused ultrasound, Trastuzumab, Herceptin, in vivo imaging, antibody therapy, 
cancer 
 
1. Introduction 
Theranostic agents are diverse in nature, from single molecules to large complexes and 
nanoparticles which have the functions of diagnosis and treatment [1]. Theranostic agents 
are labelled with one or more probes (multimodal imaging), allowing real-time imaging of the 
therapeutic by a number of imaging modes such as MRI, PET, ultrasound or optical imaging 
[2-4].  
Theranostic Nanoparticles have gained significant attention due to their properties and 
characteristic advantages for their use in cancer. Nano-theranostics have raised hopes for 
treating cancer using imaging and therapy combined in one nanoparticle [5] .  
The data derived from imaging using theranostics provide information for a) drug 
biodistribution, b) monitoring of the therapeutic effect e.g. diminishing of tumour growth, c) 
interactions of the drug with receptors, d) mechanisms of action, and e) metabolism & 
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clearance. Overall, theranostics provide information how the in vivo biodistribution and 
clearance of the potential therapeutic agent develop. This in turn allows adjustment of 
treatment parameters (e.g. dosage, timings) to best enhance the therapeutic effects [6]. 
Labelled antibodies are an important group of theranostics as they can provide insight on the 
cancer target expression levels [7,8]. Labelled antibodies have been suggested for detecting 
and treating breast cancer[9].   
Multifunctional nanoparticles that label tumours for additional imaging have been 
increasingly introduced in the field of oncology research [10]. These nanoparticles are usually 
coupled with targeting ligands such as antibodies for cancer biomarker targeting  [11].  
Therapeutic nanoparticles are coupled to antibodies for specific deliver of their cargo to 
disease cells [12]. Recently antibodies and or their versions are suggested for coupling on a 
variety of theranostic nanoparticles for better specificity and precision medicine [13-15]. 
Antibodies including Her-2 antibody coupled with radiolabels, MRI labels and or fluorescent 
labels have been suggested as theranostics [16-18]. 
Focused Ultrasound mediated drug delivery has recently raised great interest [19,20]. The 
method is suited to enhancing the delivery of nanoparticles in tumours for triggered release 
and targeted drug delivery [21]. It also allows for thermally sensitive liposomal drug delivery, 
enhancing delivery through sonoporation as well as improving drug delivery to the brain [20].     
Along with chemotherapy, hyperthermia has experienced the development of techniques as 
safe and effective to treat certain forms of cancer [22]. In particular, the use of High Intensity 
Focused Ultrasound (HIFU or FUS) allows the non-invasive heating of internal tissue areas to 
coagulation temperatures, effectively destroying targeted tumour tissue [23,24]. Lower 
power settings may also be used to induce sub-lethal (normally < 43oC), highly localised 
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hyperthermia that does not damage tissues directly. There have been a number of recent 
reports discussing the effects of such mild hyperthermia on blood irrigation and the enhanced 
uptake of therapeutic agents [25]. The combination of mild hyperthermia and 
thermoresponsive chemotherapy agents has also emerged as a recent development in 
Thermodox clinical phase III [26]. 
The method of focused ultrasound mediated hyperthermia drug delivery has been harnessed 
for other carriers or macromolecules however to a much lesser extent. In a recent study, it 
has been used to deliver B3 mAb antibody in axenograft murine cancer model, suggesting 
that this method could be developed for the delivery of radio-immunotherapy in tumours 
[27]. Recently Cetuximab was also delivered in mice in a similar fashion, showing an 
improvement on anti-tumour effect [28].  
Trastuzumab is a monoclonal antibody that binds to HER2/neu receptors, blocking human 
Epidermal Growth Factor Receptor 2 (HER-2) downstream signalling and inhibiting cancer 
cells proliferation. The HER2 gene encodes a transmembrane tyrosine kinase receptor that 
belongs to the Epidermal Growth Factor Receptor (EGFR) family. This family of receptors 
includes four members (EGFR/HER1, HER2, HER3 and HER4) that function by stimulating 
growth factor signalling pathways [29,30]. In 1998, Trastuzumab, under the brandname 
Herceptin ®, received FDA approval for the treatment of breast cancer [31]. At the same time 
FDA approved HercepTest (Dako, Denmark) for diagnosis of HER2 expression [31,32]. 
Preclinical and clinical studies have clearly demonstrated that the combination 
of Trastuzumab with small molecule chemotherapeutics (e.g. emtasine Kadcyla®, antibody 
drug conjugates) significantly prolongs the survival of patients with HER2-positive metastatic 
breast cancer [33]. In a very recent study lapatinib, a tyrosine kinase inhibitor in clinical 
6 
 
development for cancer and a potent dual inhibitor of Epidermal Growth Factor Receptor was 
combined with Trastuzumab showing impressive effects on the disease free survival 
parameter of patients that underwent the treatment [34].  
Since 2005, significant work has been done in the area of imaging, also including Trastuzumab 
as targeting molecule [35].  Dual labelled fluorescence and radio-labeled Trastuzumab has 
been tested to diagnose tumours in mice [36-38]. Labelling of Trastuzumab for MRI has been 
proved more challenging and more sophisticated approaches have been introduced [39]. 
With the aim to understand the potential effect of hyperthermia on antibody targeted 
theranostics (including nanotheranostics) this study investigates the biodistribution of 
labelled antibody in the tumour with and without Focused Ultrasound treatment. In this work, 
we report on the effects of FUS-induced mild hyperthermia on the uptake of Trastuzumab to 
murine xenograft tumours. The localisation of the antibodies (with a covalently attached dye) 
was tracked using a Near Infrared Fluorescence (NIRF) imaging system. 
2. Materials and Methods 
Unless otherwise stated, Trastuzumab/Herceptin was from Genentech (San Francisco CA, 
USA), XenoLight CF 750 NIRF dye and electrophoresis reagents from Perkin Elmer (Waltham 
MA, USA), buffers and cell reagents from GE Healthcare (UK) while other chemicals were from 
Sigma Aldrich (St. Louis MI, USA). 
2.1 XL750-Trastuzumab conjugation 
Trastuzumab (0.5 mL, 21 mg/mL) was buffer exchanged using a PD-10 column to Dulbecco's 
phosphate buffered saline (DPBS) with pH adjusted to 8.3 with redistilled triethylamine. 
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Antibody fractions were identified by absorbance at 280 nm. XenoLight CF 750 NHS (0.5 
µmole; ‘XL750’) previously dissolved in anhydrous DMSO (50 µL) was then slowly 
added with vigorous vortexing. Then mixture was then left stirring at r.t. for 1 h before re-
separating on the PD-10, run in DPBS alone. Conjugation appeared to be almost complete (> 
90 %) with little dye retained on the column. The resulting deep blue solution was split into 
200 µL portions for storage at -20 oC. Estimated final concentration was 5 mg/mL antibody, 
0.24 µmol/mL XL750. Absorbance bands for a diluted sample were 280 nm (0.67 AU; protein) 
and 750 nm (> 2 AU; NIRF dye), fluorescence peaked at 785 nm on excitation at 750 nm. 
Samples of the labelled antibody were analysed by SDS-PAGE using 4-20 % tris-glycine non-
reducing gels and highlighting protein bands with silver stain (SilverQuest, Sigma Aldrich). No 
significant differences were seen before and after incubation for 7 min at 42 oC, suggesting 
that the antibody should be stable to mild hyperthermia. 
2.2 Cell culture and tumor generation  
IGROV-1 (ovarian cancer moderately expressing Her-2 receptor), SKOV-3 (ovarian cancer 
highly expressing Her-2 receptor) and BT474 (breast cancer highly expressing Her-2 receptor) 
cells were routinely cultured in medium supplemented with fetal calf serum 10 % v/v. When 
cells reached 80-90 % confluence, they were harvested and prepared for implantation in mice. 
Post harvesting, cells were washed in saline and counted using a haemocytometer.  
Accordingly with the cell counting an equal volume of saline containing the cells was mixed 
with matrigel (Geltrex, Gibco). For the tumor generation, 5x 106 cells contained in 50 % 
matrigel mixture were inoculated subcutaneously on both flanks of 8 weeks old SHO mice 
(Charles River, Germany). After about 2 weeks, the formed tumours on each flank had 
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reached an average diameter of 5-6 mm. All experiments were approved by the Home office 
UK.  Imaging and treatments were performed in n=3 animals per group. 
2.3 FUS-induced hyperthermia 
Mice were treated with FUS-induced hyperthermia using a Therapy and Imaging Probe 
System (TIPS, Philips Research, Briarcliff NY, USA). Under isoflurane anesthesia they were 
placed on a warmed gel pad over an ultrasound absorbing mat. Two or three fine-wire 
thermocouples (T-type, 40 ga, Physitemp Instruments Inc, Cifton NJ, USA) were implanted 
above and below the target tumour and temperatures recorded (0.1 oC, 0.1 s resolutions) 
during the treatment.  Thereafter, the target tumour was covered by ultrasound gel and the 
TIPS placed at a distance of 88 mm from the skin surface of the right-side tumour. Each FUS 
insonation was delivered at a frequency of 1.0 MHz, 99.9 % cycle duty and 12-15 W of acoustic 
power actively adjusted according to the attained and target (42 oC) temperatures. Once this 
was reached, insonation was continued for 3-5 min without further temperature increase.    
2.4 Near Infrared Fluorescence Imaging 
The tumour bearing mice were injected intravenously with XL750-Trastuzumab (200 µL of 1 
mg/mL; ~ 8 mg/kg mouse body weight) in sterile mM HEPES pH 7.4 with 5% glucose (w/v). 
The injections were performed with anaesthetized mice using a syringe driver connected to a 
cannula inserted in the tail vein. The injection rate used was 400 µL/min. immediately post 
injection, each anaesthetised animal was placed into the Maestro EX (Perkin Elmer) for 
imaging. The MaestroEX (Perkin Elmer) settings were adjusted to Xenolight750 fluorescence: 
excitation filter 684-729 nm band-pass, emission filter 745 nm long-pass, and liquid crystal 
filter 740-950 nm in 10 nm steps. Image stacks were then collected at regular time points 
during the study. The resulting stacks underwent multispectral analysis compared to 
previously collected data for XL750-Trastuzumab using the supplied software (v. 3.0.1.2). The 
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processed grey scale images where then brightness balanced in groups and false coloured 
using ImageJ (v. 1.49f http://imagej.nih.gov/ij/, 1997-2015).  
 
3.Results  
The combination of a small animal FUS guided by real-time temperature measurements from 
implanted thermocouples allows the application of localised and repeatable hyperthermia 
without deviations from the target temperature (see Figure 1). In turn, NIRF imaging allows 
us to monitor the resulting changes in distribution and tumour uptake of a labelled material 
in real-time.  Other methods of preclinical imaging such as MRI and PET (SPECT/CT) suffer 
from significantly longer setup and image acquisition times although resolution is 
substantially better [40]. The TIPS/NIRF combination we designed in our study allows the 
imaging of drug biodistribution 1-2 minutes after insonation and repeated imaging at ~ 2 min 
intervals following, for periods of several hours because the animal is allowed to regain 
consciousness [41]. This gives greater confidence in the drug biodistribution behaviours that 
are imaged. 
NIRF optical imaging is non-hazardous (no radioactivity) preclinical and enables the tracking 
of the NIRF signal to ~ 1 cm deep inside the mouse body with high sensitivity. The short depth 
of the signal detection can be circumvented by rotating the mouse from ventral to dorsal 
position to provide information of the labelled drug accumulation in the RES (reticulo 
endothelial system, in particular liver and spleen) organs of the animal [42]. In our study we 
used NIRF imaging to detect the distribution of labelled Trastuzumab in the tumour (see 
supplementary video). 
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3.1 Effect of focused ultrasound treatment on labelled antibody biodistribution 
and tumoural uptake  
Trastuzumab biodistribution was first studied without hyperthermia treatment. In Figure 2, 
mice were imaged from the dorsal side showing a steady and continuous accumulation in 
both IGROV-1 tumours, reaching its maximum at 24-48 h (Figure 2 upper panel and Sup. 
Figure S2 and S6) post injection. We also observed during the first hours an accumulation of 
the NIRF signal potentially coming from the kidneys which disappeared as soon as the animal 
urinated (Supplementary material Figure S2). On the ventral side, fluorescence accumulated 
principally in the liver and the bladder over the same period, as the consequence of kidney 
clearance previously described (Supplementary material Figure S3).  
 
The effects of the application of FUS-induced mild hyperthermia on tumoural uptake were 
then examined (figure 2, middle panel). The temperature was monitored using 
thermocouples (Figure S5).The selected hyperthermia regimen was 41 oC for 5 min (this is 
brief compared to other Focused Ultrasound hyperthermia studies recently reviewed [43]). 
The change in apparent tumour uptake was noticed within 4 h, with a significant accumulation 
of NIRF signal in the treated by FUS area. But when the tumour was excised, only a small 
increase in accumulation was observed.  
In order to improve the uptake, we repeated the FUS treatment at different time intervals 
post injection (see Figure 2 and 3). The effect of repetition of FUS induced hyperthermia led 
to a substantial increase in antibody accumulation in the area of the heated tumour.  Excision 
of the tumour itself was performed at selected time points after the last application of the 
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FUS. After excision, the heated right-hand tumours presented a substantially more NIRF signal 
compared to the left-hand controls (NO-FUS treatment) but only for these mice that received 
repetition of the Focused Ultrasound treatments (Figure 3). This also shows that after one 
short treatment of hyperthermia there is an apparent increase in the fluorescent signal on 
the animal but a smaller increase of the concentration of Trastuzumab in the excised tumour. 
This might be due to the fact that tumour excision was immediate after application of 
hyperthermia indicating that the signal coming from the tumour on the living animal is from 
the blood vessels and tissues surrounding the tumour. This effect from hyperthermia 
application was reported by Khaibullina et al. who also described a large accumulation of the 
antibodies in the surrounding muscle and skin [44].  
However the effect was evident when FUS-induced hyperthermia was repeated twice or 
thrice at different time points. The benefit of the use of FUS to improve the uptake of antibody 
therapeutics was already demonstrated [27] but in our study we observed a clear response in 
the antibody uptake upon repetition of thermal dosing that is dependent the number of 
repetition of  FUS applications.  
 
The NIRF signal coming from the label that is attached to Trastuzumab appeared to be 
retained in the tumours for several days either without or with FUS treatment (supplementary 
figures Fig S2 and Fig S4). This might be coming from Trastuzumab as the antibody has a very 
long half-life (28 days) [45]. Whether NIRF dye stays attached to the antibodies or not 
distributed in the tumours remains to be investigated. It is however likely that the signal 
comes from the antibody–label conjugate as the small  NIRF molecule clears out of the animal. 
We also observed that the intensity of the signal appeared to be strong for at least 7 days (see 
12 
 
Supp. Material Figures S2 and S4). In a recent study the biological properties of Trastuzumab 
were not affected after the application of the effect of hyperthermia [46]. 
 
3.2 NIRF signal assessment in FUS treated tumours versus non treated tumours 
 As expected, without FUS treatment, the antibody uptake appeared to be the same in both 
tumours having similar sizes and development, and possibly the same vascularisation.  
 In Figure 4, we quantify the NIRF brightness from area matched regions (e.g. centre of the 
tumour) of left and right hand tumours, compared to a shoulder muscle considered as control.  
 
In Figure 4, we quantify the NIRF brightness from area matched regions (e.g. centre of the  
tumour) of left and right hand tumours, in the absence of FUS, or in the presence of 1 or 3 
rounds of FUS, in order to confirm the effect of treatment  on tumour accumulation. 
Conscientious of the nature of the NIRF signal and the problems that arise from its absolute 
quantification, we propose here a relative way to assess the magnitude of the physiological 
events observed so far, using shoulder muscle brightness as control.  
When the fluorescent antibody was injected it was distributed to the two tumours to the 
same extent (Figure 4a and 4b). Without FUS treatment uptake appeared to be the same in 
both tumours, as expected. Tumours presented similar sizes and development possibly having 
the same vascularisation. While injected fluorescent antibody distributed to the two tumours to the 
same extend (Figure 4a and 4b), after 1 round of FUS treatment the heated tumour (right tumour) 
presented clearly an increase of 2-3 fold (Figure 4c) in NIRF signal intensity. After 3 rounds of 
FUS treatment the gain in NIRF signal was estimated to be 3-4 fold (figure 4d) . This method 
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of assessment is considering the intensity of the signal and not the total phenomenon e.g. 
AUC of signal intensity versus time. 
We performed the same quantification on tumours excised from mice, sacrificed at 5 h post 
treatment with 3xFUS immediately after the application of the last FUS hyperthermia (Figure 
5). Figure 5c presents the NIRF signal analysis derived from the excised tumours coming from 
a small matched region (e.g. centre of the tumour), indicating that for that area a 2-fold 
increase in NIRF-antibody signal. These results demonstrate that 3 rounds of mild 
hyperthermia accelerate and increase the tumoral uptake of the antibody therefore changing 
the pharmacokinetics of the therapy. The tumours were excised immediately after the 
application of the last FUS induced hyperthermia. 
 
3.5 Uptake comparison between several proteins and tumour models  
In order to better understand the phenomenon of tumoral uptake induced by hyperthermia, 
two NIRF labelled non-tumour specific proteins: IgG and albumin, were also tested in mice 
bearing IGROV-1 tumours as before. Both presented similar uptake trends as the anti-Her2 
antibodies in response to 3xFUS induced hyperthermia (see Figure 6 upper panel). This result 
suggests that the presence of the receptor in the tumour is not the limiting factor in the rate 
of uptake and the enhancement of antibody accumulation to the tumour when hyperthermia 
is applied and for a defined period (at least 4h as measured). It is possible that antibody 
specific interaction is occurring post this time point. Further studies will focus to investigate 
the effect of hyperthermia on specific antibody receptor interactions and their later 
intracellular fate. 
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The effects of the 3 rounds of FUS treatment (right tumour) on the XL750 Trastuzumab 
accumulation were assessed on two other different tumour models: the ovarian SKOV-3 and 
the breast cancer BT474 cell lines, which express higher level of HER2 receptor than IGROV-
1. [47,48].  
The level of Her-2 expression of the cancer cell lines appeared not to affect the biodistribution 
of the Trastuzumab in tumours after 3x FUS treatments (Figure 6, lower panel). The 
comparison between the cell lines suggest that tumoural uptake of antibodies under the 
effect of FUS hyperthermia and for the period of treatment is not restricted by the levels of 
HER-2 receptors but to wider phenomena. Here, we hypothesise that the vascularisation and 
its permeability of the tumour are key obstacles to overcome in order to increase the 
concentration of antibodies and or their conjugates in tumour tissue. However, post 
extravasation these nanosized structures need to diffuse and interact with receptors on the 
cell surface. 
4. Discussion 
In this study we investigated the effect of focused ultrasound induced hyperthermia on 
Trastuzumab concentration in the tumour after intravenous administration in xenograft mice. 
The application of mild hyperthermia offers the possibility to accelerate and increase the 
accumulation in the tumours of Trastuzumab antibody in agreement with previous study [44]. 
In the study presented by Khaibullina et al. and Wang et al hyperthermia was applied for 8-
15 min and only once [27,44].  In our studies the repetition of mild hyperthermia induced by 
FUS appears to have an additive effect on the uptake of the macromolecule by the tumour. 
Our results indicate that the hyperthermia effect on the tumour and its increased 
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extravasation is independent on the specificity of the macromolecule to a receptor 
overexpressed in the tumour at least during the first hours post injection as similar increase 
in concentration is appearing using Albumin or IgG or Trastuzumab in IGROV-1 cells. The 
concentration of the macromolecule in the heated tumour (right tumour) is always larger 
than the concentration on the unheated tumour (left tumour). Imaging of the labelled 
antibodies Trastuzumab and IgG as well as albumin indicate that hyperthermia affects 
significantly affect their uptake by tumoral tissue. For the case of Trastuzumab the uptake 
appears to be dependent on the repetitions of FUS induced treatments. In our study we 
performed the short treatments only thrice. As most antibodies have long halflives these FUS 
treatments could be performed repeatedly during the blood circulation of the therapeutic. 
This methodology has definitely a clinical significance, but a better understanding and 
handling of the method are required to achieve improved specific tumour targeting. Despite 
good experimental and clinical observation on the positive effects of hyperthermia [22] more 
physiological studies need to be performed in order to understand what are the physiological 
changes and their magnitude upon the gradual raise of temperature from 37 oC to 43 oC. 
Hyperthermia increase locally the blood flow and the perfusion of the tumour and as 
described by Li et al. will also permeate the tumoural tissue for several hours [49].  It is 
possible that the enhanced vascular permeability could enhance even further the 
accumulation of the antibody after the last treatment. 
This induced focused hyperthermia methodology could be compatible with a different 
imaging modality and not only with optical imaging but with MRI and PET which are widely 
present in clinical premises. 
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Nanotheranostics coupled to antibodies may have the potential to lead to a new era in 
treating tumours with a real time monitoring of the therapy. Targeted nanoparticles can 
provide an important tool for diagnosis and drug therapy and/or radiotherapy [50,51]. 
Nanoparticles provide a versatile tool that can accommodate the targeting ligand as well as 
the imaging probe. Their composition can provide additional imaging abilities (e.g. iron oxide 
nanoparticles)[52]. 
Antibody coupled nanotheranostics have the potential to provide personalisation of the 
treatment with a better adjustment to the patient therapeutic needs. Real time imaging of 
the treatment provides a great tool to the clinicians to make decisions for immediate 
treatments. Image guided focused ultrasound can enhance the accumulation of these 
nanotheranostics in the tumour and potentially improve the therapeutic effect. For instance 
if the nanotehranostic carries radiotherapy or highly toxics drugs. Nanotheranostics in 
combination with hyperthermia, can offer a better control of the therapy and can optimize 
the treatments with an improved targeting and reduce the dosage of administered drug.  The 
entire procedure of image guided drug delivery has the potential to accelerate therapy and 
might reduce the cost and risks of treatment.  
5 Conclusion 
In this study we have shown that FUS-induced short duration hyperthermia applied non-
invasively and locally in the tumour can increase the accumulation of macromolecular drugs 
such as antibodies specifically in the tumours. The effect is dependent on the repetition of 
focused ultrasound treatments. 
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Figure 1: TIPS focused ultrasound (FUS); (left) overview of the equipment showing the 
water-filled transducer chamber, the thermocouple interface, and the control PC; (right) 
schematic of the in vivo configuration with the transducer (a) raised such that the ultrasound 
biconic (b) focuses just above the skin surface over the tumour (c). The mouse is surrounded 
with warmed, degassed ultrasound gel (d) and placed on an ultrasound absorbing mat (e) to 
prevent reflections off the table. Temperature monitoring is via two or three fine-wire 
thermocouples (f) implanted around the tumour. 
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Figure 2: NIRF in vivo imaging of mice with  bilateral implanted tumours (IGROV-1) at time 
point post-injection of Xl750-herceptin (~ 8 mg/kg). FUS induced hypothermia treatment was 
either omitted (top) or applied at 1 h (middle) or 1 h, 2 h, and 3 h 30 (bottom) on the right tumour. 
The difference in labelled antibody uptake is clear and lasts for more than a week.  
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Figure 3: Comparisons of in vivo and excised IGROV-1 tumours labeled XL750-herceptin NIRF 
from mice treated with no, 1, 2, or 3 rounds of FUS hyperthermia to the right hand tumour.  The 
animals were sacrificed at 1 h, 2 h 30 min, and 4 h post injection.  
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Figure 4: Assessed brightness from area matched regions of left and right hand tumours, 
compared to a muscle control for mice undergoing either (a) is an example of the areas of 
interest selected. (b)  no FUS treatment; (c) 1 round of FUS treatment at 30 min or (d) 3 
rounds of FUS treatment at 30 min, 2 h, and 3 h 30; all post injection of XL750-herceptin (~ 8 
mg/kg).  
(a) 
25 
 
 
 
 
 
 
 
 
                                                    
                                                    
                                                    
                                                    
                                                    
                                                    
                                                    
                                                    
                                                    
                                                    
                                                    
                                                    
left right
0
200
400
600
800
1000
1200
1400
1600
1800
2000
2200
2400
A
v
e
ra
g
e
 p
ix
e
l 
b
ri
g
h
tn
e
s
s
 (
A
U
)
(a) (c) 
Figure 5: NIRF imaging of representative left (no FUS) 
and right (3x FUS) sacrificed 5h post injection of 
Xl750-herceptin. (a) false colour and (b) greyscale 
images taken from the excised tumours, with the latter 
showing the matched area regions used to calculate  (c) 
mean and 1 SD pixel brightness (n=3). 
(b) 
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Figure 6: Upper panel: Uptake of XL750-Albumin and XL750-IgG in IGROV-1 tumours after 
3xFUS treatments. Lower Panel: Comparison 3x FUS treatments on XL750-Trastuzumab 
(XL750-T) uptake into IGROV-1, SKOV-3 and BT474 cell line tumours. NIRF in vivo imaging 
of mice at t = 4h post-injection of Xl750-herceptin (~ 8 mg/kg). FUS induced hypothermia treatment 
was carried out at 1h, 2h, and 3h30.  
XL750-Albumin XL750-IgG 
SKOV-3 BT474 
XL750- T XL750-T 
IGROV-1 
XL750- T 
